Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells
Journal of Microbiology and Biotechnology · 10.04.2025 · 35
DOI: 10.4014/jmb.2412.12032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, online erschienen am 10.04.2025. Verfasst von Dong-Hwan Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Amino Acid Transport System ASC, Glutaminase, Minor Histocompatibility Antigens. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Pancreatic cancer, a leading cause of cancer-related deaths, is characterized by increased dependence on glutamine metabolism. Telaglenastat (CB-839), a glutaminase (GLS) inhibitor targets glutamine metabolism; however, its efficacy as monotherapy is limited owing to metabolic adaptations. In this study, we demonstrated that CB-839 effectively inhibited cell growth in pancreatic cancer cells, but activated the general control nonderepressible 2 (GCN2)-activating transcription factor 4 (ATF4) signaling pathway. ATF4 knockdown reduced glutamine transporter alanine, serine, and cysteine transporter 2 (ASCT2) expression, glutamine uptake, and cell viability under glutamine deprivation-recovery conditions, confirming its protective role in mitigating glutamine-related metabolic stress. Notably, the combination of CB-839 and the ASCT2 inhibitor V-9302 demonstrated a synergistic effect, significantly suppressing pancreatic cancer cell survival. These findings highlight ATF4 and ASCT2 as crucial therapeutic targets and indicate that dual inhibition of GLS and ASCT2 may enhance treatment outcomes for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
- Department of Microbiology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, D. H., Kim, D. J., Park, S. J., Jang, W. J., & Jeong, C. H. (2025). Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. Journal of Microbiology and Biotechnology, 35. https://doi.org/10.4014/jmb.2412.12032
Vancouver
Kim DH, Kim DJ, Park SJ, Jang WJ, Jeong CH. Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells. Journal of Microbiology and Biotechnology. 2025;35. doi:10.4014/jmb.2412.12032
BibTeX
@article{Kim2025,
author = {Kim, Dong-Hwan and Kim, Dong Joon and Park, Seong-Jun and Jang, Won-Jun and Jeong, Chul-Ho},
title = {Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells},
journal = {Journal of Microbiology and Biotechnology},
year = {2025},
volume = {35},
doi = {10.4014/jmb.2412.12032}
}
EUVIMED